Opendata, web and dolomites

denovoSkin SIGNED

Personalized, bio-engineered skin grafts for the permanent treatment of skin defects

Total Cost €


EC-Contrib. €






 denovoSkin project word cloud

Explore the words cloud of the denovoSkin project. It provides you a very rough idea of what is the project "denovoSkin" about.

patented    16    5m    fda    trade    every    stamp    solving    treatment    scarrring    site    logistics    classified    plan    personalized    considerable    market    orphan    dermo    fits    risking    world    granted    intense    hence    automate    swissmedic    starting    invested    clinical    intervention    structure    fast    autologous    sound    permanent    drug    savings    global    biopsy    entire    movement    leads    off    therapy    epidermal    scars    denovoskin    investment    suffer    graft    impair    burden    psychosocial    worldwide    defects    surgical    optimal    financial    instrument    function    de    17    ema    skin    economic    avoids    interventions    follow    reduce    medical    shortage    life    donor    homecare    patient    excision    quality    debilitating    wounds    rehabilitation    considerably    atmp    issue    sized    leaves    burns    restore    performance    57m    significantly    last    painful    sme    standard    engineered    health    50m    assuring    disfiguring    bio    deployment    patients    corrective    transplantation    autografting    minimal    human    designation    quantities    projected    outstanding    care    surgeries   

Project "denovoSkin" data sheet

The following table provides information about the project.


Organization address
city: ZURICH
postcode: 8006
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Project website
 Total cost 3˙571˙237 €
 EC max contribution 2˙499˙866 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-10-01   to  2020-09-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CUTISS AG CH (ZURICH) coordinator 2˙499˙866.00


 Project objective

Every year in the world, more than 50M patients suffer from skin defects (e.g. burns, excision, etc.) and need surgical intervention to restore skin function. Standard of care, skin autografting, very often leaves these patients with scars. Scars are permanent and disfiguring, and can also be painful and highly debilitating. Indeed, they may also impair movement and growth, and require several follow-up surgeries, intense homecare and psychosocial rehabilitation. Hence, scars significantly affect patient’s quality of life, along with the economic burden for the health-care system. Furthermore, in the case of large wounds, donor site shortage represents a real clinical issue.

denovoSkin™ is a patented, personalized, autologous bio-engineered human skin graft classified as Advanced Therapy Medical Product (ATMP). It is engineered in large quantities starting-off from a stamp-sized skin biopsy of the patient, thus solving the donor site shortage issue. Moreover, because of its dermo-epidermal structure, denovoSkin™ leads to minimal scarrring after transplantation. Its outstanding performance could considerably reduce or even avoids further corrective interventions, allowing for considerable savings in terms of costs. denovoSkin™ is also granted with Orphan Drug Designation for the treatment of burns by Swissmedic, EMA and FDA.

So far, more than €17.5M have been invested over the last 16 years of research into the development and the clinical testing of denovoSkin™. To have denovoSkin™ fully projected at a European and global level we need a further investment of €3.57M to automate its production, de-risking the entire denovoSkin™ project by assuring a real delivery to patients worldwide while providing optimal logistics and quality of product.

The proposed work in Phase 2 of the SME instrument fits into our overall plan to reach the market by contributing the financial resources needed to plan a fast sound wider deployment of denovoSkin™ and its market uptake.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DENOVOSKIN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DENOVOSKIN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

TuneFork (2018)

Mobile technology that brings personalized audio into your life

Read More  

PrasinoMed (2018)

First in the world ecological and sustainable cream for wound care, based on microalgaprasinococcus capsulatus

Read More  

GREEN WHS (2019)


Read More